<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="9" family="AdvC2870" color="#000000"/>
	<fontspec id="font1" size="9" family="AdvC2866" color="#000000"/>
	<fontspec id="font2" size="9" family="AdvC2867" color="#000000"/>
	<fontspec id="font3" size="10" family="AdvSMyr-SB" color="#000000"/>
	<fontspec id="font4" size="9" family="AdvPSMP13" color="#000000"/>
	<fontspec id="font5" size="9" family="AdvP4C4E74" color="#000000"/>
	<fontspec id="font6" size="8" family="AdvPSMy-R" color="#000000"/>
<text top="50" left="54" width="114" height="8" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="text">Conﬁrmation of pregnancy.</text>
<text top="50" left="173" width="115" height="8" font="font1" id="p1_t2" reading_order_no="2" segment_no="1" tag_type="text">A commercial kit to detect</text>
<text top="61" left="45" width="243" height="8" font="font1" id="p1_t3" reading_order_no="3" segment_no="1" tag_type="text">hCG levels in urine (KAT Quick HCG, KAT Medical, http://</text>
<text top="72" left="45" width="243" height="8" font="font1" id="p1_t4" reading_order_no="4" segment_no="1" tag_type="text">www.katmedical.com; the performance of this kit was</text>
<text top="83" left="45" width="243" height="8" font="font1" id="p1_t5" reading_order_no="5" segment_no="1" tag_type="text">validated against another commercial kit, QuickVue, Quidel</text>
<text top="94" left="45" width="243" height="8" font="font1" id="p1_t6" reading_order_no="6" segment_no="1" tag_type="text">Corporation, http://www.quidel.com) was used to screen for</text>
<text top="105" left="45" width="243" height="8" font="font1" id="p1_t7" reading_order_no="7" segment_no="1" tag_type="text">pregnancy at enrollment and each visit. Women with positive</text>
<text top="116" left="45" width="212" height="8" font="font1" id="p1_t8" reading_order_no="8" segment_no="1" tag_type="text">urine pregnancy tests were conﬁrmed by ultrasound.</text>
<text top="127" left="54" width="90" height="8" font="font0" id="p1_t9" reading_order_no="9" segment_no="3" tag_type="text">Other laboratory tests.</text>
<text top="127" left="147" width="141" height="8" font="font1" id="p1_t10" reading_order_no="10" segment_no="3" tag_type="text">A vaginal wet mount was examined</text>
<text top="138" left="45" width="243" height="8" font="font1" id="p1_t11" reading_order_no="11" segment_no="3" tag_type="text">microscopically at each visit to detect motile trichomonads</text>
<text top="149" left="45" width="243" height="8" font="font1" id="p1_t12" reading_order_no="12" segment_no="3" tag_type="text">and candida using standard laboratory methods [10]. We did</text>
<text top="160" left="45" width="50" height="8" font="font1" id="p1_t13" reading_order_no="13" segment_no="3" tag_type="text">not test for</text>
<text top="160" left="100" width="55" height="8" font="font2" id="p1_t14" reading_order_no="14" segment_no="3" tag_type="text">N. gonorrhoeae</text>
<text top="160" left="160" width="15" height="8" font="font1" id="p1_t15" reading_order_no="15" segment_no="3" tag_type="text">and</text>
<text top="160" left="179" width="55" height="8" font="font2" id="p1_t16" reading_order_no="16" segment_no="3" tag_type="text">C. trachomatis,</text>
<text top="160" left="239" width="49" height="8" font="font1" id="p1_t17" reading_order_no="17" segment_no="3" tag_type="text">because the</text>
<text top="171" left="45" width="243" height="8" font="font1" id="p1_t18" reading_order_no="18" segment_no="3" tag_type="text">prevalence of these organisms has been very low (1%) in</text>
<text top="182" left="45" width="117" height="8" font="font1" id="p1_t19" reading_order_no="19" segment_no="3" tag_type="text">recent studies in Malawi [14].</text>
<text top="200" left="45" width="218" height="10" font="font3" id="p1_t20" reading_order_no="20" segment_no="6" tag_type="title">Study Questionnaires and Physical Examination</text>
<text top="213" left="45" width="243" height="8" font="font1" id="p1_t21" reading_order_no="21" segment_no="7" tag_type="text">Demographic, clinical, acceptability, and adherence ques-</text>
<text top="224" left="45" width="243" height="8" font="font1" id="p1_t22" reading_order_no="22" segment_no="7" tag_type="text">tionnaires were completed at enrollment and follow-up visits.</text>
<text top="235" left="45" width="243" height="8" font="font1" id="p1_t23" reading_order_no="23" segment_no="7" tag_type="text">To monitor adherence, women were asked to return the</text>
<text top="246" left="45" width="243" height="8" font="font1" id="p1_t24" reading_order_no="24" segment_no="7" tag_type="text">empty tube and used applicators at the PTE follow-up visits.</text>
<text top="257" left="45" width="221" height="8" font="font1" id="p1_t25" reading_order_no="25" segment_no="7" tag_type="text">The amount of gel used in each tube was also assessed.</text>
<text top="275" left="45" width="138" height="10" font="font3" id="p1_t26" reading_order_no="26" segment_no="8" tag_type="title">Adverse Experience Reporting</text>
<text top="287" left="45" width="243" height="8" font="font1" id="p1_t27" reading_order_no="27" segment_no="9" tag_type="text">Trained clinicians and nurses conducted a speculum-aided</text>
<text top="298" left="45" width="243" height="8" font="font1" id="p1_t28" reading_order_no="28" segment_no="9" tag_type="text">pelvic examination at each visit to detect mucosal abnormal-</text>
<text top="309" left="45" width="243" height="8" font="font1" id="p1_t29" reading_order_no="29" segment_no="9" tag_type="text">ities. Adverse events (AEs) by severity (grade 1, mild; 2, moderate;</text>
<text top="320" left="45" width="243" height="8" font="font1" id="p1_t30" reading_order_no="30" segment_no="9" tag_type="text">3, severe; 4, life threatening; and 5, death) and relatedness to</text>
<text top="331" left="45" width="243" height="8" font="font1" id="p1_t31" reading_order_no="31" segment_no="9" tag_type="text">product use were recorded. Serious AEs were deﬁned based on</text>
<text top="343" left="45" width="191" height="8" font="font1" id="p1_t32" reading_order_no="32" segment_no="9" tag_type="text">Code of Federal Regulations ICH Guidelines [15].</text>
<text top="361" left="45" width="47" height="10" font="font3" id="p1_t33" reading_order_no="33" segment_no="10" tag_type="title">Objectives</text>
<text top="373" left="45" width="243" height="8" font="font1" id="p1_t34" reading_order_no="34" segment_no="11" tag_type="text">The primary objective of this study was to determine whether</text>
<text top="384" left="45" width="243" height="8" font="font1" id="p1_t35" reading_order_no="35" segment_no="11" tag_type="text">intermittent intravaginal metronidazole gel antibiotic treat-</text>
<text top="395" left="45" width="243" height="8" font="font1" id="p1_t36" reading_order_no="36" segment_no="11" tag_type="text">ment would reduce the frequency of BV among HIV-</text>
<text top="406" left="45" width="243" height="8" font="font1" id="p1_t37" reading_order_no="37" segment_no="11" tag_type="text">uninfected and -infected African women. We hypothesized</text>
<text top="417" left="45" width="243" height="8" font="font1" id="p1_t38" reading_order_no="38" segment_no="11" tag_type="text">that repeated (intermittent) presumptive treatment with an</text>
<text top="428" left="45" width="243" height="8" font="font1" id="p1_t39" reading_order_no="39" segment_no="11" tag_type="text">intravaginal antibiotic regimen would restore normal vaginal</text>
<text top="439" left="45" width="243" height="8" font="font1" id="p1_t40" reading_order_no="40" segment_no="11" tag_type="text">ﬂora, enhance BV clearance (conversely, limit persistence),</text>
<text top="450" left="45" width="116" height="8" font="font1" id="p1_t41" reading_order_no="41" segment_no="11" tag_type="text">and decrease BV recurrence.</text>
<text top="468" left="45" width="88" height="10" font="font3" id="p1_t42" reading_order_no="42" segment_no="13" tag_type="title">Outcome Measures</text>
<text top="481" left="45" width="243" height="8" font="font1" id="p1_t43" reading_order_no="43" segment_no="14" tag_type="text">The primary endpoint was proportion of women testing</text>
<text top="492" left="45" width="243" height="8" font="font1" id="p1_t44" reading_order_no="44" segment_no="14" tag_type="text">positive for BV based on the Nugent score at each visit, both</text>
<text top="503" left="45" width="243" height="8" font="font1" id="p1_t45" reading_order_no="45" segment_no="14" tag_type="text">cross-sectionally (between study arms) and longitudinally</text>
<text top="514" left="45" width="243" height="8" font="font1" id="p1_t46" reading_order_no="46" segment_no="14" tag_type="text">(within study arms). The secondary outcome measure was the</text>
<text top="525" left="45" width="223" height="8" font="font1" id="p1_t47" reading_order_no="47" segment_no="14" tag_type="text">effect of treatment on clearance and recurrence of BV.</text>
<text top="543" left="45" width="55" height="10" font="font3" id="p1_t48" reading_order_no="48" segment_no="15" tag_type="title">Sample Size</text>
<text top="556" left="45" width="243" height="8" font="font1" id="p1_t49" reading_order_no="49" segment_no="16" tag_type="text">In this trial a sample size of 832 HIV-uninfected women and</text>
<text top="567" left="45" width="243" height="8" font="font1" id="p1_t50" reading_order_no="50" segment_no="16" tag_type="text">832 HIV-infected women was assumed adequate based on the</text>
<text top="578" left="45" width="243" height="8" font="font1" id="p1_t51" reading_order_no="51" segment_no="16" tag_type="text">longitudinal comparisons to provide a power of 87% or more</text>
<text top="589" left="45" width="243" height="8" font="font1" id="p1_t52" reading_order_no="52" segment_no="16" tag_type="text">to detect a reduction of 33% or more in the prevalence of BV</text>
<text top="600" left="45" width="243" height="8" font="font1" id="p1_t53" reading_order_no="53" segment_no="16" tag_type="text">from a baseline prevalence of 30% (two treatment arms, type</text>
<text top="611" left="45" width="40" height="8" font="font1" id="p1_t54" reading_order_no="54" segment_no="16" tag_type="text">1 error of</text>
<text top="610" left="88" width="5" height="8" font="font4" id="p1_t55" reading_order_no="55" segment_no="16" tag_type="text">a</text>
<text top="610" left="95" width="7" height="9" font="font5" id="p1_t56" reading_order_no="56" segment_no="16" tag_type="text">¼</text>
<text top="611" left="104" width="173" height="8" font="font1" id="p1_t57" reading_order_no="57" segment_no="16" tag_type="text">0.05 and 10% loss during 1 y of follow-up).</text>
<text top="629" left="45" width="68" height="10" font="font3" id="p1_t58" reading_order_no="58" segment_no="19" tag_type="title">Randomization</text>
<text top="641" left="45" width="243" height="8" font="font1" id="p1_t59" reading_order_no="59" segment_no="20" tag_type="text">Block-randomized computer-generated lists were prepared in</text>
<text top="652" left="45" width="243" height="8" font="font1" id="p1_t60" reading_order_no="60" segment_no="20" tag_type="text">the US and were stratiﬁed by clinic and HIV status. The study</text>
<text top="663" left="45" width="243" height="8" font="font1" id="p1_t61" reading_order_no="61" segment_no="20" tag_type="text">product was provided to the site in a sealed envelope (opaque</text>
<text top="674" left="45" width="243" height="8" font="font1" id="p1_t62" reading_order_no="62" segment_no="20" tag_type="text">and padded to avoid damage) with no identiﬁers other than</text>
<text top="685" left="45" width="243" height="8" font="font1" id="p1_t63" reading_order_no="63" segment_no="20" tag_type="text">the study and clinic identiﬁcation numbers. These envelopes</text>
<text top="696" left="45" width="243" height="8" font="font1" id="p1_t64" reading_order_no="64" segment_no="20" tag_type="text">were issued from a central pharmacy at the study site after</text>
<text top="708" left="45" width="243" height="8" font="font1" id="p1_t65" reading_order_no="65" segment_no="20" tag_type="text">the women had been counseled and screened, and had given</text>
<text top="719" left="45" width="243" height="8" font="font1" id="p1_t66" reading_order_no="66" segment_no="20" tag_type="text">their informed consent to enroll. The study pharmacist and</text>
<text top="50" left="306" width="243" height="8" font="font1" id="p1_t67" reading_order_no="67" segment_no="2" tag_type="text">coordinator regularly carried out checks on the order of</text>
<text top="61" left="306" width="243" height="8" font="font1" id="p1_t68" reading_order_no="68" segment_no="2" tag_type="text">randomization and matched enrollment identiﬁcation num-</text>
<text top="72" left="306" width="243" height="8" font="font1" id="p1_t69" reading_order_no="69" segment_no="2" tag_type="text">bers with clinic and HIV status. The packaging and labeling of</text>
<text top="83" left="306" width="243" height="8" font="font1" id="p1_t70" reading_order_no="70" segment_no="2" tag_type="text">the study product was performed in the US by an</text>
<text top="94" left="306" width="243" height="8" font="font1" id="p1_t71" reading_order_no="71" segment_no="2" tag_type="text">independent team. Investigators, research workers, and</text>
<text top="105" left="306" width="243" height="8" font="font1" id="p1_t72" reading_order_no="72" segment_no="2" tag_type="text">participants were masked about the study product. Neither</text>
<text top="116" left="306" width="243" height="8" font="font1" id="p1_t73" reading_order_no="73" segment_no="2" tag_type="text">the study pharmacist at the research site in Malawi or study</text>
<text top="127" left="306" width="243" height="8" font="font1" id="p1_t74" reading_order_no="74" segment_no="2" tag_type="text">coordinator was aware of the details of the study product.</text>
<text top="138" left="306" width="243" height="8" font="font1" id="p1_t75" reading_order_no="75" segment_no="2" tag_type="text">Both treatment and placebo gels had comparable appear-</text>
<text top="150" left="306" width="243" height="8" font="font1" id="p1_t76" reading_order_no="76" segment_no="2" tag_type="text">ance, consistency, and packaging. Participants were random-</text>
<text top="161" left="306" width="161" height="8" font="font1" id="p1_t77" reading_order_no="77" segment_no="2" tag_type="text">ized at enrollment (baseline) visit (V1.0).</text>
<text top="179" left="306" width="87" height="10" font="font3" id="p1_t78" reading_order_no="78" segment_no="4" tag_type="title">Statistical Methods</text>
<text top="191" left="306" width="243" height="8" font="font1" id="p1_t79" reading_order_no="79" segment_no="5" tag_type="text">Data were checked for completeness and consistency and</text>
<text top="202" left="306" width="243" height="8" font="font1" id="p1_t80" reading_order_no="80" segment_no="5" tag_type="text">entered locally in a database. All analyses of the primary</text>
<text top="213" left="306" width="243" height="8" font="font1" id="p1_t81" reading_order_no="81" segment_no="5" tag_type="text">outcome were performed separately for HIV-uninfected and</text>
<text top="225" left="306" width="243" height="8" font="font1" id="p1_t82" reading_order_no="82" segment_no="5" tag_type="text">-infected women using the intent to treat (rather than as</text>
<text top="236" left="306" width="243" height="8" font="font1" id="p1_t83" reading_order_no="83" segment_no="5" tag_type="text">treated) approach. The proportion of events occurring in the</text>
<text top="247" left="306" width="243" height="8" font="font1" id="p1_t84" reading_order_no="84" segment_no="5" tag_type="text">two study arms were cross-sectionally compared at each visit.</text>
<text top="258" left="306" width="243" height="8" font="font1" id="p1_t85" reading_order_no="85" segment_no="5" tag_type="text">Analyses were also conducted to compare events longitudi-</text>
<text top="269" left="306" width="243" height="8" font="font1" id="p1_t86" reading_order_no="86" segment_no="5" tag_type="text">nally within the same study arms between visits. Chi-square</text>
<text top="280" left="306" width="243" height="8" font="font1" id="p1_t87" reading_order_no="87" segment_no="5" tag_type="text">(exact test) and other nonparametric tests were used for these</text>
<text top="291" left="306" width="243" height="8" font="font1" id="p1_t88" reading_order_no="88" segment_no="5" tag_type="text">comparisons. Generalized estimating equation log binomial</text>
<text top="302" left="306" width="243" height="8" font="font1" id="p1_t89" reading_order_no="89" segment_no="5" tag_type="text">models based on relative risk ratio assessed longitudinal</text>
<text top="313" left="306" width="243" height="8" font="font1" id="p1_t90" reading_order_no="90" segment_no="5" tag_type="text">associations of treatment with BV after controlling for other</text>
<text top="324" left="306" width="243" height="8" font="font1" id="p1_t91" reading_order_no="91" segment_no="5" tag_type="text">covariates measured at multiple visits to account for repeated</text>
<text top="336" left="306" width="243" height="8" font="font1" id="p1_t92" reading_order_no="92" segment_no="5" tag_type="text">visit correlation of these repeated observations. Univariable</text>
<text top="347" left="306" width="243" height="8" font="font1" id="p1_t93" reading_order_no="93" segment_no="5" tag_type="text">(unadjusted) relative risks (RRs) and adjusted RRs, and 95%</text>
<text top="358" left="306" width="243" height="8" font="font1" id="p1_t94" reading_order_no="94" segment_no="5" tag_type="text">conﬁdence intervals (CIs) are presented. Statistical signiﬁ-</text>
<text top="369" left="306" width="151" height="8" font="font1" id="p1_t95" reading_order_no="95" segment_no="5" tag_type="text">cance was considered to be two-sided</text>
<text top="369" left="460" width="4" height="8" font="font2" id="p1_t96" reading_order_no="96" segment_no="5" tag_type="text">p</text>
<text top="369" left="477" width="18" height="8" font="font1" id="p1_t97" reading_order_no="97" segment_no="5" tag_type="text">0.05.</text>
<text top="380" left="315" width="234" height="8" font="font1" id="p1_t98" reading_order_no="98" segment_no="12" tag_type="text">We further analyzed BV clearance and recurrence in the</text>
<text top="391" left="306" width="243" height="8" font="font1" id="p1_t99" reading_order_no="99" segment_no="12" tag_type="text">subgroups of women to determine the impact of intravaginal</text>
<text top="402" left="306" width="243" height="8" font="font1" id="p1_t100" reading_order_no="100" segment_no="12" tag_type="text">antibiotic treatment among HIV-uninfected and -infected</text>
<text top="413" left="306" width="243" height="8" font="font1" id="p1_t101" reading_order_no="101" segment_no="12" tag_type="text">women. We deﬁned BV clearance as a positive BV test at</text>
<text top="424" left="306" width="243" height="8" font="font1" id="p1_t102" reading_order_no="102" segment_no="12" tag_type="text">baseline with a negative BV test (ﬁrst negative test) in a follow-</text>
<text top="435" left="306" width="243" height="8" font="font1" id="p1_t103" reading_order_no="103" segment_no="12" tag_type="text">up visit, and BV recurrence as a positive BV test at baseline</text>
<text top="446" left="306" width="243" height="8" font="font1" id="p1_t104" reading_order_no="104" segment_no="12" tag_type="text">with a negative BV test (ﬁrst negative test) in a follow-up visit</text>
<text top="458" left="306" width="243" height="8" font="font1" id="p1_t105" reading_order_no="105" segment_no="12" tag_type="text">and becoming BV positive (ﬁrst positive test) in a subsequent</text>
<text top="469" left="306" width="243" height="8" font="font1" id="p1_t106" reading_order_no="106" segment_no="12" tag_type="text">visit. We used Kaplan-Meier survival analyses to estimate</text>
<text top="480" left="306" width="243" height="8" font="font1" id="p1_t107" reading_order_no="107" segment_no="12" tag_type="text">median time to clearance and recurrence events and the</text>
<text top="491" left="306" width="243" height="8" font="font1" id="p1_t108" reading_order_no="108" segment_no="12" tag_type="text">cumulative probability of these events stratiﬁed by study arm</text>
<text top="502" left="306" width="243" height="8" font="font1" id="p1_t109" reading_order_no="109" segment_no="12" tag_type="text">among HIV-uninfected and -infected women. Cox propor-</text>
<text top="513" left="306" width="243" height="8" font="font1" id="p1_t110" reading_order_no="110" segment_no="12" tag_type="text">tional hazard models were used to control for various factors</text>
<text top="524" left="306" width="243" height="8" font="font1" id="p1_t111" reading_order_no="111" segment_no="12" tag_type="text">and determine the major predictors of these events. Treat-</text>
<text top="535" left="306" width="243" height="8" font="font1" id="p1_t112" reading_order_no="112" segment_no="12" tag_type="text">ment, number of sex partners, frequency of sex, vaginal pH,</text>
<text top="546" left="306" width="57" height="8" font="font1" id="p1_t113" reading_order_no="113" segment_no="12" tag_type="text">douching, and</text>
<text top="546" left="365" width="42" height="8" font="font2" id="p1_t114" reading_order_no="114" segment_no="12" tag_type="text">T. vaginalis</text>
<text top="546" left="410" width="139" height="8" font="font1" id="p1_t115" reading_order_no="115" segment_no="12" tag_type="text">were included in these Cox models</text>
<text top="557" left="306" width="243" height="8" font="font1" id="p1_t116" reading_order_no="116" segment_no="12" tag_type="text">(all were time-dependent except for treatment). Statistical</text>
<text top="568" left="306" width="132" height="8" font="font1" id="p1_t117" reading_order_no="117" segment_no="12" tag_type="text">signiﬁcance was determined by a</text>
<text top="569" left="441" width="4" height="8" font="font2" id="p1_t118" reading_order_no="118" segment_no="12" tag_type="text">p</text>
<text top="568" left="445" width="24" height="8" font="font1" id="p1_t119" reading_order_no="119" segment_no="12" tag_type="text">-value</text>
<text top="568" left="482" width="67" height="8" font="font1" id="p1_t120" reading_order_no="120" segment_no="12" tag_type="text">0.05. All analyses</text>
<text top="580" left="306" width="238" height="8" font="font1" id="p1_t121" reading_order_no="121" segment_no="12" tag_type="text">were conducted using SAS (version 8.2; http://www.sas.com).</text>
<text top="598" left="306" width="80" height="10" font="font3" id="p1_t122" reading_order_no="122" segment_no="17" tag_type="title">Study Monitoring</text>
<text top="610" left="306" width="243" height="8" font="font1" id="p1_t123" reading_order_no="123" segment_no="18" tag_type="text">This study was monitored by a ﬁve-member Data and Safety</text>
<text top="621" left="306" width="243" height="8" font="font1" id="p1_t124" reading_order_no="124" segment_no="18" tag_type="text">Monitoring Board. Study conduct and review of clinical AEs</text>
<text top="632" left="306" width="207" height="8" font="font1" id="p1_t125" reading_order_no="125" segment_no="18" tag_type="text">were also monitored by two independent monitors.</text>
<text top="650" left="306" width="114" height="10" font="font3" id="p1_t126" reading_order_no="126" segment_no="21" tag_type="title">Provision of Clinical Care</text>
<text top="663" left="306" width="243" height="8" font="font1" id="p1_t127" reading_order_no="127" segment_no="22" tag_type="text">Routine clinical care for all women (including continuous</text>
<text top="674" left="306" width="243" height="8" font="font1" id="p1_t128" reading_order_no="128" segment_no="22" tag_type="text">counseling, provision of condoms, and treatment of STIs) was</text>
<text top="685" left="306" width="243" height="8" font="font1" id="p1_t129" reading_order_no="129" segment_no="22" tag_type="text">provided by the project at no cost. HIV-infected women were</text>
<text top="696" left="306" width="243" height="8" font="font1" id="p1_t130" reading_order_no="130" segment_no="22" tag_type="text">provided additional support by trained counselors and</text>
<text top="707" left="306" width="243" height="8" font="font1" id="p1_t131" reading_order_no="131" segment_no="22" tag_type="text">community educators. Specialized clinical care for HIV-</text>
<text top="719" left="306" width="243" height="8" font="font1" id="p1_t132" reading_order_no="132" segment_no="22" tag_type="text">infected women was provided by project clinicians and</text>
<text top="742" left="45" width="85" height="7" font="font6" id="p1_t133" reading_order_no="133" segment_no="23" tag_type="text">www.plosclinicaltrials.org</text>
<text top="742" left="477" width="72" height="7" font="font6" id="p1_t134" reading_order_no="135" segment_no="24" tag_type="text">February | 2007 | e10</text>
<text top="742" left="289" width="16" height="7" font="font6" id="p1_t135" reading_order_no="134" segment_no="25" tag_type="text">0004</text>
<text top="26" left="427" width="122" height="7" font="font6" id="p1_t136" reading_order_no="0" segment_no="0" tag_type="title">Intermittent use of Intravaginal Gels</text>
</page>
</pdf2xml>
